EVOLUTION OF TARGETED THERAPIES FOR THYROID CARCINOMA.
Trans Am Clin Climatol Assoc
; 130: 255-265, 2019.
Article
em En
| MEDLINE
| ID: mdl-31516190
ABSTRACT
Although treatment options for patients with advanced and metastatic thyroid carcinoma were historically limited, developments in the past 15 years in understanding the pathogenesis of these malignancies have permitted identification of novel targeted therapies to improve outcomes. Five individual drugs and one combination therapy have achieved regulatory approval since 2011, all showing improvements in progression-free survival or high response rates. More selective targeting of mutated oncogenic kinases is leading to increasing efficacy with fewer toxicities, at least in early human trials. Collaborations among endocrinologists, medical oncologists, and patients are making advances possible, where such developments appeared impossible merely 15 years ago.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Glândula Tireoide
/
Carcinoma Neuroendócrino
/
Adenoma Oxífilo
/
Adenocarcinoma Folicular
/
Inibidores de Proteínas Quinases
/
Câncer Papilífero da Tireoide
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article